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Abstract
Background: A previous study at Indiana University demonstrated a reduction in myocardial infarction (MI) 
incidence with increased frequency of cardiac catheterization (CATH) in liver transplant (LT) candidates. A 
strict protocol for performing CATH based upon predefined risk factors, rather than non-invasive testing 
alone, was applied to a subgroup (2009-2010) from that study. CATH was followed by percutaneous coronary 
intervention (PCI) in cases of significant coronary artery disease (CAD; ≥50% stenosis). The current study 
applies this screening protocol to a larger cohort (2010-2016) to assess post-LT clinical outcomes. 
Results: Among 811 LT patients, 766 underwent stress testing (94%), and 559 underwent CATH (69%) of 
whom 10% had CAD requiring PCI. The sensitivity of stress echocardiography in detecting significant CAD was 
37%. Predictors of PCI included increasing age, male gender and personal history of CAD (p<0.05 for all). 
Compared to patients who had no CATH, patients who underwent CATH had higher mortality (p=0.07), 
and the hazard rates (HR) for mortality increased with CAD severity [normal CATH (HR: 1.35 [95% CI: 0.79, 
2.33], p=0.298); non-obstructive CAD (HR: 1.53 [95% CI: 0.84, 2.77], p=0.161); and significant CAD (HR: 1.96 
[95% CI: 0.93, 4.15], p=0.080)]. Post-LT outcomes were compared to the 2009-2010 subgroup from the 
previous study and showed similar 1-year overall mortality (8% and 6%, p=0.48); 1-year MI incidence (<1% 
and <1%, p=0.8); and MI deaths as portion of all deaths (3% and 9%, p=0.35). 
Conclusion: Stress echocardiography alone is not reliable in screening LT patients for CAD. Aggressive CAD 
screening with CATH is associated with low rate of MI and cardiac mortality and validates the previously 
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Background
The prevalence of coronary artery disease (CAD) is rising among LT candidates. Approximately 25% of LT 
candidates with traditional coronary risk factors may have moderate CAD (stenosis ≥ 50%) even while 
asymptomatic, and those with severe CAD have increased cardiac mortality (1). Therefore, aggressive pre-LT 
ischemic evaluation is necessary to assess cardiac function and identify clinically significant cardiovascular 
disease. Current pre-LT guidelines endorse initial assessment with electrocardiogram (EKG) and non-invasive 
stress testing (2, 3). The 2012 American Heart Association/American College of Cardiology Foundation 
Scientific Statement for Cardiac Disease Evaluation and Management among Kidney and Liver Transplant 
Candidates recommend screening with non-invasive modalities in patients with 3 or more cardiac risk factors, 
regardless of functional status (3). The American Association for the Study of Liver Diseases Practice Guideline 
was updated in 2013 to recommend stress echocardiogram (SE), whether exercise or pharmacologic, as the 
initial cardiovascular screening tool in all LT candidates (2).
Despite these recommendations, there is a large degree of variation between clinical practice guidelines and 
transplant center practice patterns with regards to who should be screened for CAD and which screening 
modality should be used (4, 5). Moreover, the clinical utility of screening asymptomatic transplant candidates 
remains unclear. Large randomized controlled trials for non-transplant patients do not recommend screening 
and revascularization of asymptomatic patients preoperatively, although these trials might not be applicable 
to the transplant population, where asymptomatic disease is prevalent (3). Moreover, LT candidates are at 
risk of hemodynamic instability due to organ dysfunction that extends beyond the cardiac system (6). Risk 
stratification of LT candidates remains challenging as data on cardiovascular mortality post-transplantation 
are based on incremental knowledge from observational studies; there are no randomized controlled trials 
that compare different screening modalities. Moreover, Framingham’s score and traditional scores do not 
accurately predict cardiovascular risk score in the preoperative transplant patients (7). In context of the 
aforementioned, further analysis of specific risk factor combinations with respect to outcomes would allow 
for more selective use of cardiac evaluation, especially given that risk stratification may be a better predictive 
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An analysis of 1221 LT patients at Indiana University Hospital found significant reduction in 1-year all-cause 
mortality, and in the incidence of MI post-transplant, with increased frequency of CATH and percutaneous 
coronary intervention (PCI) over 3 time periods between 2000-2010 (9). Period A (2000-2004) included 527 
patients who were initially referred to general cardiology, all of them had a 2-dimensional echocardiogram, 
and CATH was at the discretion of the consulting cardiologist. Period B (2005-2008) included 520 patients 
who were evaluated by select cardiologists, and these patients underwent SE with or without CATH. Period C 
(2009-2010) included 174 patients who were evaluated by a single cardiologist. Since 2009, our center has 
adopted a policy of cardiac evaluation by a single cardiologist including stress testing and CATH. CATH was 
indicated based on risk factors even in the presence of negative stress test findings. These risk factors 
included age, smoking history, diabetes, hypertension requiring medications, history of CAD, family history of 
CAD, and obesity. A lower threshold for PCI was adopted at ≥50% stenosis in a major vessel (left anterior 
descending artery or right coronary artery) or critical disease, defined as stenosis ≥70% in at least moderate-
sized branch vessels.
This study is a follow-up of the previous analysis and will help in further understanding cardiovascular disease 
in the LT population. The objective of this study is twofold. First, it builds on the previous study by further 
analyzing the role of universal stress testing and use of CATH based on predefined risk factors over a longer 
duration (2010-2016) and in a larger population. The efficacy of stress testing alone to identify CAD in the 
liver failure population will be assessed. Second, this study reports the long-term outcomes of an aggressive 
CAD screening protocol with CATH based on risk factors, and a lower threshold for coronary intervention. 
One-year all-cause mortality, 1-year MI incidence, and MI deaths are reported, as well as long-term survival.
Methods
Data Collection
All patients undergoing LT at a single center between 2010 and 2016 were evaluated by a single cardiologist. 
The record of each of these patients was reviewed individually and collected data included: demographics 
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ejection fraction, CATH status (if patient underwent CATH; degree of stenosis, whether there was an 
intervention or not, and immediate complications), initial stress testing status and the associated result in 
case of SE (normal test, abnormal echocardiogram component, abnormal EKG component but normal 
echocardiogram component, non-diagnostic test) or nuclear test (normal or abnormal). Data related to the 
following cardiovascular risk factors were also analyzed: body mass index, diabetes mellitus, hypertension 
requiring medications, tobacco use (never user, current user at the time of evaluation, former user, and 
number of tobacco pack-years if there was a smoking history), personal history of CAD, and family history of 
CAD (negative, immediate, or distant family history). Collection of pre- and post-CATH laboratory values can 
be found in Supplement 1. Data were stored and updated on an online secure password-protected access-
controlled portal. Only personnel with approval from our Institutional Review Board and who had Indiana 
University credentials were given access to the database.
Definitions: CATH Results
CATH results were defined as negative (no intervention) or positive (CAD ≥50% stenosis in a major vessel or 
≥70% stenosis in at least a moderate-sized branch vessel requiring intervention with PCI +/- balloon 
angioplasty). Degree of stenosis was classified into three categories: normal coronaries, non-obstructive CAD 
(<50% stenosis; or ≥50% stenosis but not in a major vessel and not requiring intervention; or revascularized 
CAD; or luminal irregularities; or minor calcifications), or significant CAD (≥50% stenosis in a major vessel or 
≥70% stenosis in at least a moderate-sized branch vessel warranting intervention).
Definitions: SE Results
SE results were defined as negative, positive, or non-diagnostic. A test was deemed negative if there were no 
wall motion abnormalities (WMA) with stress, no EKG changes, and no chest pain; or the SE component was 
normal with baseline EKG abnormalities or equivocal EKG component. A positive stress test had WMA (new 
or worsening with stress) +/- EKG changes +/- chest pain; or positive EKG changes per criteria without WMA 
(10). A stress test was considered non-diagnostic if it had equivocal findings; or 85% of maximum predicted 
heart rate (220-age) was not achieved; or the test was terminated due to fatigue, hypotension, hypertension, 
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Our CATH Protocol
Femoral approach was used in all cases along with a combined fluoroscopic and Doppler ultrasound 
technique for access. Further details can be found in Supplement 2. Drug-eluting stents were routinely used 
since 2009 with at least 3 months of dual antiplatelet therapy, except for two patients who received at least 
6-8 weeks of therapy due to the need for urgent LT. Dual antiplatelet therapy was generally restarted post-LT 
to continue for a total of 1 year post-PCI.
Postoperative MI and Cardiac Mortality
LT outcomes and deaths were followed and recorded by the Department of Surgery staff members. To 
identify 1-year cardiac mortality, the record of each patient who received LT during 2010-2016 and died was 
reviewed individually. The incidence of postoperative MI within 1 year after transplant date was investigated 
using International Classification of Diseases Ninth Revision Clinical Modification (ICD-9-CM) diagnosis codes, 
ICD-10-CM diagnosis codes, as well as troponin values. Troponin value of 0.03 ng/ml was used as the upper 
limit of normal which meets the 99th percentile for normal range troponin values. Obtained values were 
filtered according to two times the upper limit of normal (>0.06 ng/ml). A total of 125 patients met the 
criteria, and their charts were reviewed individually. MI was defined as a troponin value more than two times 
the upper limit of normal with supporting evidence of EKG changes and clinical presentation.
Statistical Analysis
We used frequency distribution to describe the proportion of patients undergoing cardiac stress testing and 
CATH in terms of factors such as patient demographics, cardiac risk factors, Model for End-stage Liver Disease 
score, and graft number. Bivariate analysis using Chi-square and Fisher’s exact tests, as appropriate, were 
conducted to examine the relationship between the aforementioned factors and results from cardiac stress 
testing or CATH. Unadjusted Kaplan-Meier analysis and age-adjusted Cox proportional hazards models were 
used to perform the survival analysis post-LT. The log-rank test was used to compare differences in survival 
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Stata version 14 (StataCorp, College Station, TX, USA). Use of center data for retrospective analysis has been 
reviewed and approved by the Indiana University Institutional Review Board. The study protocol for this 
research conformed to the Declaration of Helsinki.
Results
Demographics
Data for a total of 811 LT patients were included in this analysis. The cohort’s median Model for End-stage 
Liver Disease score was 22, age 57 years, body mass index 28 kg/m2, with 67% males, and 89% identified as 
Caucasians (Table 1). Regarding common cardiac risk factors, 30% were diabetic, 39% with hypertension, 50% 
with any history of tobacco use, 7% had a personal history of CAD and 37% with immediate family history of 
CAD. The most common etiologies for cirrhosis were hepatitis C (30%), followed by alcoholic liver disease 
(22%), and non-alcoholic steatohepatitis (20%). Of note, many patients had more than one factor contributing 
to their liver disease. Other less common cirrhosis etiologies are listed in Supplemental Table 1. 
Stress Testing Results
There were 811 patients who underwent LT during the study period, of whom 766 had stress testing (94%) 
(Figure 1, Table 2). Notably, this refers to an initial stress test prior to CATH, if CATH was done. For example, 8 
patients already had prior CATH at the time of evaluation when a subsequent stress test was obtained; these 
were counted among patients who did not undergo initial stress testing. SE was normal in 613 (80%) patients. 
SE was abnormal in 63 (8%) patients, of whom 37 (59%) patients had WMA and 26 (41%) patients had EKG 
changes but normal SE component. Non-diagnostic SE were reported in 66 (9%) patients. Significant 
differences (p ≤ 0.05) between SE result categories were found in diabetes mellitus and personal history of 
CAD (Table 2). Nuclear stress testing was performed in 24 (3%) patients, 21 (88%) of which were normal and 3 
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Total number of patients who had CATH was 559 (69%) patients (Table 3). Coronary arteries were found to be 
normal in 314 (56%) patients, non-obstructive CAD was found in 190 (34%) patients, and significant or 
obstructive CAD requiring intervention was found in 55 (10%) patients. Among the 55 patients who 
underwent CATH with PCI, 29 (53%) had PCI to the left anterior descending artery, 14 (25%) to the right 
coronary artery, 8 (15%) to the left circumflex artery, 3 (5%) to the posterior descending artery, 7 (13%) to a 
diagonal branch, and 6 (11%) to a marginal branch. Sixteen patients (29%) had PCI to two or more coronary 
arteries and/or branches. Significant differences (p ≤0.05) between the normal coronaries, non-obstructive 
CAD, and significant CAD groups were found in age, gender, hypertension, diabetes mellitus, and personal 
history of CAD (Table 3). Characteristics of patients who had positive CATH and negative CATH were 
compared (Figure 2).
Immediate CATH-related complications were seen in 6 (1%) patients; 3 with positive CATH, and 3 with 
negative CATH (Table 3). These included dissection of left iliac artery, dissection of left circumflex and obtuse 
marginal arteries treated with stents, allergic reaction to platelets treated with an antihistamine agent and 
steroids, minor groin hematoma (2 patients), and minor dissection of right external iliac artery that was 
treated conservatively (no luminal obstruction; no vascular occlusion device used). 
SE as a Screening Tool; Pre-CATH Stress Testing
The number of patients who underwent stress testing followed by CATH was 534 (66%), of these 515 (96%) 
patients had SE testing and 19 (4%) patients had nuclear stress testing (Figure 1). Of the patients who had SE, 
63 (12%) were positive, 404 (78%) were negative, and 48 (9%) were equivocal. Of note, 1 patient had positive 
CATH but initial stress testing was deferred. Of the patients who had nuclear testing, 3 (16%) had a positive 
test (1 patient had positive CATH) and 16 (84%) had a negative test (4 patients had positive CATH). Of the 48 
patients who had equivocal SE, 8 (16%) patients had a positive CATH.
The number of patients who had a normal initial stress test not followed by CATH was 214 patients (28%), 
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in 238 (57%) of these patients, showed non-obstructive disease in 152 (36%) patients, and 30 (7%) patients 
had significant CAD and received intervention. The sensitivity of SE in detecting significant CAD requiring 
intervention was found to be 37% (Table 4). In other words, 63% of patients who received coronary 
intervention had a negative screening SE. 
Pre- and Post-CATH Laboratory Values, Transfusions, and Acute Kidney Injury
The mean laboratory values were obtained for all 559 patients who underwent CATH within 1 day prior to 
CATH. Mean hemoglobin was 11.4±2.0 g/dL, mean INR 1.5±0.4, mean platelet count 89.9±60.7 × 109/L, and 
mean creatinine 1.2±1.1 mg/dL. No major bleeding events were recorded while minor bleeding events 
occurred in 14 patients (2.5%). A total of 10 patients (1.8%) received packed red blood cell transfusions pre-
CATH and 12 patients (2.1%) post-CATH; 78 patients (14.0%) received platelet transfusions pre-CATH and 30 
patients (5.3%) post-CATH; 183 patients (2.3%) received fresh frozen plasma and/or prothrombin complex 
concentrate pre-CATH and 82 patients (14.7%) post-CATH. Acute kidney injury was present in 24 patients 
(4.3%) up to 7 days post-CATH. Resolution of acute kidney injury occurred prior to discharge in 22 of the 24 
patients, one of whom required temporary renal replacement therapy. The remaining 2 patients with no 
resolution of acute kidney injury were followed up by the outpatient nephrology service. One patient 
required intermittent hemodialysis with complete recovery while the other was diagnosed with hepatorenal 
syndrome and later underwent renal transplantation.
Cumulative Survival and Postoperative Cardiovascular Events
The mean follow-up period was 55.9 months with a standard deviation of 29.1 months, while the median was 
52.7 months with a range of (0-109.1) months. Unadjusted Kaplan-Meier plot from 7-year cumulative survival 
analysis was used to compare patients who had no pre-transplant CATH, had normal coronaries, non-
obstructive CAD, and significant CAD requiring intervention (Figure 3). Over time, the likelihood of surviving 
was lowest for those with severe CAD requiring intervention. The log rank test indicated that there were 
more estimated deaths in the CATH groups (normal, non-obstructive, severe) compared to the group with no 
indication for CATH (reference group), though not statistically significant (p=0.07). In the age-adjusted Cox 
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to those with no indication for CATH [CATH normal (HR: 1.35 [95% CI: 0.79, 2.33], p=0.298); non-obstructive 
CAD (HR: 1.53 [95% CI: 0.84, 2.77], p=0.161); severe CAD requiring intervention (HR: 1.96 [95% CI: 0.93, 4.15], 
p=0.080)].
There were 64 total deaths at 1 year post-LT. There were 6 MI events at 1 year (3 in the normal CATH group, 2 
in the non-obstructive group, and 1 in the severe CAD group), of which 2 were fatal (1 in the normal CATH 
group and 1 in the non-obstructive group). In comparison, there were 11 deaths and 1 fatal MI event at 1 year 
in the 2009-2010 cohort. Hence, post-LT 1-year MI mortality and overall 1-year mortality in this study were 
comparable to the 2009-2010 cohort in the previous study who were managed using the same protocol (3% 
vs. 9% (of deaths) [p=0.35] and 8% vs. 6% (of all patients) [p=0.48], respectively) (Figure 4).
The average timing for the incidence of cardiovascular event, indicated by elevated troponin, was 10 days 
post-transplant with a median of 4 days. The average peak troponin was 0.54 ng/ml and the median was 0.24 
ng/ml. Cardiology team was consulted on 25 patients based on clinical symptoms, EKG changes, or increasing 
troponin values. Troponin was found to be elevated in setting of acute coronary syndrome, arrhythmias 
(atrial fibrillation, atrial flutter, and bradycardia with pauses), angiographically-proven coronary spasm, 
pericarditis, demand ischemia and stress cardiomyopathy in context of acute illness or profound anemia or 
shock requiring the use of vasopressors. 
Discussion
Historically, it was thought that patients with end-stage liver disease are at lower risk of developing CAD as a 
result of hemodynamic and hormonal imbalances, as well as abnormal hepatic synthetic function seen in 
cirrhosis (11, 12). However, recent studies have shown that the prevalence of CAD in LT patients is equal to or 
greater than the general population (13, 14). Carey et al. evaluated 37 patients over age 50 awaiting LT with 
coronary angiography. Moderate CAD was defined as 30-70% stenosis, while severe CAD was defined as ≥70% 
stenosis, and the overall frequency of severe CAD was found to be 16% (15). Patients without risk factors 
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important risk factor for moderate or severe CAD. Another study evaluated 161 patients over age 45 with 
angiography as part of LT evaluation and found that the prevalence of moderate (50% to 70%) to severe 
(>70%) CAD was 26% (14). The patients were more likely to be men and have hypertension or diabetes 
mellitus. Results from the present study show that significant CAD (≥50% stenosis in a major vessel 
warranting intervention) occurred in 10% of patients who underwent CATH or 7% of the total study 
population of 811 patients. Presence of CAD in this study was significantly associated with increasing age, 
male gender, personal history of CAD, diabetes mellitus and hypertension. These were all factors included in 
the risk factor screening adopted by our center in 2009, with the addition of smoking history, family history of 
CAD, and obesity. Results from this study suggest that these factors constitute an appropriate list for 
screening in this population.
Pre-transplant echocardiographic findings have yielded conflicting results with regards to predicting post-
transplant morbidity and mortality (16-18). When stress tests were used as primary screening tools, they had 
low sensitivity and positive predictive value for asymptomatic patients, rendering them ineffective tools for 
this purpose (1, 19-21). In addition, higher MI rates were noted when dobutamine SE was the primary 
screening test in our center (9). The sensitivity and specificity of SE in detecting significant angiographically-
proven CAD were calculated in our study as 37% and 89%, respectively. In comparison, Harinstein et al. found 
the sensitivity to be 13%, with comparable specificity of 85% in a total of 105 patients (22). These results 
suggest that SE is a poor screening test for CAD in LT candidates. The low sensitivity, or high false-negative 
event rate, may be due to inadequate response of beta-receptors to sympathetic stimulation in cirrhotic 
patients and/or concomitant use of beta-blockers for variceal bleeding prophylaxis, reducing the ability to 
reach target heart rates and subsequent induction of WMA with adequate stress levels (6).
Coronary computed tomography angiography (CCTA) may be an acceptable alternative to CATH in patients 
with low risk of CAD (1). However, its quality is affected by patient’s clinical and physical status and it has 
poor positive predictive value of detecting significant CAD requiring revascularization (1, 23-25). Further 
studies are needed to evaluate the role of CCTA in detecting CAD in LT population, since to this date, there 
have been no reports comparing CCTA to CATH and the current studies included relatively small sample sizes. 
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volume used was not reported. The amount of contrast used for CCTA is center-dependent; a typical CCTA 
requires 90-120 mL of iodine contrast (26). Therefore, it might not be a good alternative for patients with 
renal dysfunction in whom a diagnostic CATH may be performed with a lower amount of contrast.
Coronary angiography has been increasingly utilized to screen for CAD among LT candidates. However, this 
practice is not currently endorsed by American Heart Association/American College of Cardiology Foundation 
or American Association for the Study of Liver Diseases guidelines and remains center-specific. Multiple 
studies have analyzed the effect of revascularization on post-transplant survival. A small study of 47 LT 
patients who underwent CATH as part of pre-transplant workup found that the presence of multivessel CAD 
was associated with decreased survival following transplantation, even in the absence of severe coronary 
artery stenosis, suggesting that coronary angiography before transplantation may have a prognostic value. 
Notably, only 2 of these patients underwent revascularization (27). Among 630 patients undergoing pre-LT 
CATH in a multicenter cohort study over a 12-year period, there was no significant difference in 1-year 
survival between patients with obstructive CAD (≥50% stenosis) of whom 53% were revascularized, and those 
without obstructive CAD (28). Satapathy et al. reported on 87 LT recipients and found that survival in patients 
who underwent CATH, with revascularization when indicated, was comparable to those presumed not to 
have CAD based on non-invasive testing (29). In our study, patients who had an indication for CATH had lower 
7-year survival as compared to those who did not undergo CATH (reference group), regardless of the CATH 
results. This indicates that the presence of certain risk factors could be an important determinant of long-
term survival. It is important to note that mortality in this study did increase with the severity of CAD, while 
there was no significant difference in survival between the normal CATH, non-obstructive CAD, and 
obstructive CAD (revascularized) groups compared to the reference group (p=0.30, p=0.16, and p=0.08, 
respectively). This finding is likely related to the small sample size in these subgroups. 
The rate of MI in our center is lower than what was previously reported in the literature. The MI rate during a 
median follow-up of 4 years was 2.8% in a German cohort of 352 LT patients that were screened per 
published guidelines (30). It is also lower than what was previously published in a review paper by Ali et al. 
comparing eight studies that used different screening modalities (31). Moreover, patients in the significant 
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than patients with no CAD. Therefore, patients with significant CAD requiring intervention have reasonable 
long-term outcomes and should not be excluded if they are otherwise good candidates for LT.
Patients with end-stage liver disease are more prone to CATH-related complications due to 
thrombocytopenia, anemia, coagulopathy, and kidney disease. Hence, they are at a higher risk of major 
bleeding, are more likely to require transfusions after CATH, and are at a higher risk of vascular complications 
such as pseudoaneurysms (32). In our study, 6 (1%) patients experienced immediate CATH-related 
complications. All cases were done using the femoral approach. Recently, a consensus published by the 
American Transplant Society recommended a radial approach in patients undergoing LT evaluation to 
improve hemostasis and reduce periprocedural complications (1). However, it is worth mentioning that our 
study (1/2010-12/2016) took place prior to the published consensus in 1/2018. In addition, the 
aforementioned recommendation favoring radial approach was based on 2 retrospectives studies. The first 
study by Huded et al. compared the rate of vascular and bleeding complications in a sample of 1071 patients 
(10% LT candidates, 90% non-LT candidates) undergoing CATH by radial approach (33). The study showed no 
difference in the rate of complications between the two groups. However, it does not directly compare radial 
and femoral approaches. Similarly, in the second study by Jacobs et al. radial CATH was performed in 82 
patients with end-stage liver disease (34). Authors found this approach to be safe in LT candidates but again 
did not directly compare outcomes with the femoral approach. The RIVAL trial was the first large trial 
comparing radial versus femoral access for PCI in patients with acute coronary syndrome (35). There was no 
statistical difference in the primary outcome of a composite of death, MI, stroke or major bleeding between 
the two arms of the trial. There were significantly fewer vascular complications in the radial access group with 
respect to hematomas and pseudoaneurysms needing closure. However, it is important to note that the rate 
of major vascular complications with the radial approach was not superior to the femoral approach at high-
volume femoral centers. A similar observation can be seen in the MATRIX trial, the largest randomized trial 
comparing radial versus femoral access in acute coronary syndrome (36). The rate of net adverse clinical 
events were similar between the radial and femoral groups at centers using predominantly femoral access, 
but the rate was higher at centers using predominantly radial access. Furthermore, a recent meta-analysis of 
randomized controlled trials in acute coronary syndrome suggests that the reported differences between the 
radial versus femoral approach may have been driven by adverse events in the femoral groups rather than 
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the LT population. Based on the aforementioned data, the patient population and operator’s experience 
might be more important for outcomes than the access site. The femoral technique used in our center was 
performed by an experienced single operator who used combined fluoroscopic and Doppler ultrasound 
guidance for optimal common femoral artery access in all cases, closure devices in more than 95% of the 
cases to reduce bleeding complications, and took appropriate precautions with reversing coagulopathies as 
necessary. Access site management in the RIVAL and MATRIX trials were left to the operator’s discretion; the 
use of ultrasound was not mandated, and only 25.6% use of closure devices was reported in the RIVAL trial. 
Our center’s technique did not result in any major bleeding events and in a minor bleeding incidence of only 
2.5%. Another point is that with radial access, in addition to using vasodilating agents, 2500-5000 units of 
intra-arterial heparin or up to 100 IU/Kg is used to prevent thrombus formation after the wire is inserted that 
may lead to radial artery occlusion (38). Heparin is not needed in the femoral approach unless PCI is required. 
This is important to consider in the LT population where the risk of bleeding is already high due to 
coagulopathy.
CATH can be considered a safe procedure in LT patients (9, 32). However, it should be acknowledged that risk 
stratification by using a combination of risk factors may be a valuable tool that could allow for more selective 
use of CATH. As above, presence of CAD in our study was significantly associated with increasing age, male 
gender, personal history of CAD, hypertension, and diabetes mellitus. These results support a protocol of 
aggressive CAD screening with CATH based on risk factors and a lower threshold for coronary intervention, as 
it is associated with low cardiac morbidity and mortality.
We acknowledge the limitations of a retrospective study including the availability of test results, and 
reliability of clinical documentation and data collection. Also, our data represents a single center’s transplant 
population which might differ from other centers. However, this might contribute to the strength of this 
study in having a single CATH operator and a strict protocol for patient selection and performing CATH. The 
rates of MI and mortality are likely underestimated in this cohort due to the retrospective design and reliance 
on available data. Additionally, delayed complications of CATH were not surveyed. Lastly, since this study only 
focuses on the preoperative LT evaluation, data collection pertaining to CAD for patients who were evaluated 
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Conclusion
This study shows that SE may not be a reliable screening tool for CAD in LT patients. The reported results 
serve as a validation of the previously published protocol by showing comparable outcomes of low rate of MI 
and cardiac mortality with aggressive CAD screening when extrapolated over a larger sample and longer 
follow-up period. Therefore, patients with significant CAD requiring intervention have reasonable long-term 
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Figure Legends
Figure 1: Consort diagram representing 811 out of 3611 candidates who underwent LT with the pre-LT testing 
and their corresponding results. LT=liver transplant, CATH=cardiac catheterization, echo=echocardiogram.
Figure 2: Cardiac risk factors of patients who had negative CATH (no intervention) compared to patients who 
had positive CATH (CAD ≥50% stenosis in a major vessel or ≥70% stenosis in at least a moderate-sized branch 
vessel requiring intervention with PCI +/- balloon angioplasty). CATH=cardiac catheterization, BMI=body mass 
index, HTN on meds=hypertension on medications, Hx of CAD=history of coronary artery disease, PY=pack-
years.
Figure 3: Unadjusted Kaplan-Meier plot from 7-year cumulative survival analysis for patients who had no pre-
transplant cardiac catheterization (CATH), had normal coronaries, non-obstructive coronary artery disease 
(CAD), and significant CAD requiring intervention. Over time, the likelihood of surviving was lowest for those 
with severe CAD requiring intervention. The log-rank test indicated that there were more estimated deaths in 
the catheterization groups (normal, non-obstructive, severe) compared to the group with no indication for 
catheterization (reference group), though not statistically significant (p=0.07). In the age-adjusted Cox 
proportional hazards model, the hazard rates (HR) of mortality increased with the severity of CAD compared 
to those with no indication for CATH [CATH normal (HR: 1.35 [95% CI: 0.79, 2.33], p=0.298); non-obstructive 
CAD (HR: 1.53 [95% CI: 0.84, 2.77], p=0.161); severe CAD requiring intervention (HR: 1.96 [95% CI: 0.93, 4.15], 
p=0.080)].
Figure 4: Comparison between our current study (2010-2016) and a time period from our previous study 
(2009-2010) using the same protocol. The percentage of catheterization, intervention, 1-year mortality, MI 
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Table 1. Demographics for 811 patients who underwent liver transplant. 
 
Number (%) 





     20 or less 374 (46%) 
     21 to 29 351 (43%) 
     30 and higher 86 (11%) 
Gender 
 
     Male 546 (67%) 
     Female 265 (33%) 
Race 
 
     White 723 (89%) 
     Black 44 (5%) 
     Other 44 (5%) 
Age (years) 
 
     Less than 30 31 (4%) 
     30 to 39 39 (5%) 
     40 to 49 112 (14%) 
     50 to 59 317 (39%) 
     60 and older 312 (38%) 
Body mass index (kg/m2) 
 
     Less than 25.0 218 (27%) 
     25.0 to 29.9 268 (33%) 
     30.0 to 34.9 219 (27%) 
     35.0 and higher 106 (13%) 
Graft number 
 
     First 786 (97%) 
     Re-transplant 25 (3%) 
Etiology of Cirrhosis* 
 
     Hepatitis C 267 (30%) 
     Alcohol 200 (22%) 
     NASH 179 (20%) 
     PSC 79 (9%) 
     Autoimmune 35 (4%) 
     PBC 34 (4%) 
     Cryptogenic 22 (2%) 
     Other 77 (9%) 
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Diabetes mellitus 
 
     No 565 (70%) 
     Yes 246 (30%) 
Hypertension 
 
     No 491 (61%) 
     Yes 320 (39%) 
Tobacco 
 
     Never 402 (50%) 
     Current (at evaluation) 126 (16%) 
     Former 283 (35%) 
Tobacco pack years 
 
     None 402 (50%) 
     1 to 20 223 (27%) 
     20 to 40 132 (16%) 
     >40 54 (7%) 




     No 756 (93%) 
     Yes 55 (7%) 




     None 466 (58%) 
     Immediate family (any) 296 (37%) 
     Distant family only 46 (6%) 
 
MELD: Model for End-stage Liver Disease, NASH: Non-Alcoholic SteatoHepatitis, PSC: Primary Sclerosing 
Cholangitis, PBC: Primary Biliary Cirrhosis. * Many patients had more than one factor contributing to 
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Table 2. Results of pre-liver transplant cardiac stress testing in 766 patients who subsequently 





Stress echocardiography results (n=742) 
 





































26 (3%) 66 (9%) 
 
21 (88%) 3 (13%) 
 RECIPIENT 
         MELD score 




     20 or less 360 
293 
(48%) 17 (46%) 7 (27%) 29 (44%) 
 
11 (52%) 3 (100%)  
     21 to 29 331 
263 
(43%) 17 (46%) 15 (58%) 28 (42%) 
 
8 (38%) 0 (0%)  
     30 and higher 75 57 (9%) 3 (8%) 4 (15%) 9 (14%) 
 
2 (10%) 0 (0%) 
 
Gender 





     Male 516 
402 
(66%) 31 (84%) 17 (65%) 48 (73%) 
 
16 (76%) 2 (67%)  
     Female 250 
211 
(34%) 6 (16%) 9 (35%) 18 (27%) 
 
5 (24%) 1 (33%)  
Race 





     White 688 
550 
(90%) 34 (92%) 23 (88%) 58 (88%) 
 
20 (95%) 3 (100%)  
     Black 40 35 (6%) 1 (3%) 1 (4%) 2 (3%) 
 
1 (5%) 0 (0%) 
 
     Other 38 28 (5%) 2 (5%) 2 (8%) 6 (9%) 
 
0 (0%) 0 (0%) 
 
Age (years) 




     Less than 30 22 20 (3%) 0 (0%) 0 (0%) 2 (3%) 
 
0 (0%) 0 (0%) 
 
     30 to 39 34 31 (5%) 0 (0%) 1 (4%) 2 (3%) 
 
0 (0%) 0 (0%) 
 
     40 to 49 108 84 (14%) 4 (11%) 4 (15%) 13 (20%) 
 
3 (14%) 0 (0%) 
 
     50 to 59 302 
254 
(41%) 13 (35%) 5 (19%) 24 (36%) 
 
4 (19%) 2 (67%)  
     60 and older 300 
224 
(37%) 20 (54%) 16 (62%) 25 (38%) 
 
14 (67%) 1 (33%)  
Body mass index 
(kg/m2) 





     Less than 25.0 202 157 7 (19%) 5 (19%) 28 (42%) 
 












This article is protected by copyright. All rights reserved 
(26%) 
     25.0 to 29.9 256 
209 
(34%) 12 (32%) 12 (46%) 15 (23%) 
 
7 (33%) 1 (33%)  
     30.0 to 34.9 207 
165 
(27%) 14 (38%) 7 (27%) 16 (24%) 
 
4 (19%) 1 (33%)  
     35.0 and higher 101 82 (13%) 4 (11%) 2 (8%) 7 (11%) 
 
5 (24%) 1 (33%) 
 
Graft number 




     First 745 
596 
(97%) 36 (97%) 24 (92%) 65 (98%) 
 
21 (100%) 3 (100%)  
     Re-transplant 21 17 (3%) 1 (3%) 2 (8%) 1 (2%) 
 
0 (0%) 0 (0%) 
 
         
 
Cardiac risk factors 
        
 
Diabetes mellitus 






     No 532 
444 
(72%) 15 (41%) 14 (54%) 44 (67%) 
 
13 (62%) 2 (67%)  
     Yes 234 
169 
(28%) 22 (59%) 12 (46%) 22 (33%) 
 
8 (38%) 1 (33%)  
Hypertension 




     No 458 
368 
(60%) 21 (57%) 13 (50%) 41 (62%) 
 
12 (57%) 3 (100%)  
     Yes 308 
245 
(40%) 16 (43%) 13 (50%) 25 (38%) 
 
9 (43%) 0 (0%)  
Tobacco 





     Never 378 
304 
(50%) 16 (43%) 15 (58%) 33 (50%) 
 
9 (43%) 1 (33%)  
     Current (at 
evaluation) 116 94 (15%) 5 (14%) 3 (12%) 11 (17%) 
 
3 (14%) 0 (0%)  
     Former 272 
215 
(35%) 16 (43%) 8 (31%) 22 (33%) 
 
9 (43%) 2 (67%)  
Tobacco pack years 





     None 378 
304 
(50%) 16 (43%) 15 (58%) 33 (50%) 
 
9 (43%) 1 (33%)  
     1 to 20 209 
159 
(26%) 12 (32%) 6 (23%) 22 (33%) 
 
8 (38%) 2 (67%)  
     20 to 40 127 
103 
(17%) 7 (19%) 4 (15%) 9 (14%) 
 
4 (19%) 0 (0%)  
     >40 52 47 (8%) 2 (5%) 1 (4%) 2 (3%) 
 
0 (0%) 0 (0%) 
 
Patient history of 
coronary 
        
 
artery disease 
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     No 714 
585 
(95%) 26 (70%) 22 (85%) 61 (92%) 
 
17 (81%) 3 (100%)  
     Yes 52 28 (5%) 11 (30%) 4 (15%) 5 (8%) 
 
4 (19%) 0 (0%) 
 
Family history of 
coronary 










     None 434 
353 
(58%) 23 (62%) 15 (58%) 34 (52%) 
 
8 (38%) 1 (33%)  
     Immediate family 
(any) 286 
220 
(36%) 14 (38%) 8 (31%) 29 (44%) 
 
13 (62%) 2 (67%)  
     Distant family only 43 37 (6%) 0 (0%) 3 (12%) 3 (5%) 
 
0 (0%) 0 (0%) 
 
 
MELD: Model for End-stage Liver Disease. * Unable to calculate p-value because of small cell values; † 3 
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Table 3. Results of pre-liver transplant cardiac catheterization in 559 patients who subsequently 
underwent liver transplant. 
  




























       
MELD score 




     20 or less 264 (47%) 151 (48%) 91 (48%) 22 (40%) 
 
2 (33%) 













     Male 391 (70%) 202 (64%) 141 (74%) 48 (87%) 
 
5 (83%) 









     White 509 (91%) 284 (90%) 173 (91%) 52 (95%) 
 
5 (83%) 













     Less than 30 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 
0 (0%) 
















Body mass index (kg/m^2) 




     Less than 25.0 127 (23%) 74 (24%) 36 (19%) 17 (31%) 
 
2 (33%) 

















     First 549 (98%) 311 (99%) 186 (98%) 52 (95%) 
 
6 (100%) 





       
Cardiac risk factors 
       
Diabetes mellitus 




     No 338 (60%) 204 (65%) 105 (55%) 29 (53%) 
 
3 (50%) 
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     No 305 (55%) 187 (60%) 92 (48%) 26 (47%) 
 
4 (67%) 









     Never 221 (40%) 124 (39%) 75 (39%) 22 (40%) 
 
1 (17%) 








Tobacco pack years 




     None 221 (40%) 124 (39%) 75 (39%) 22 (40%) 
 
1 (17%) 












Patient history of coronary 
       
artery disease 




     No 506 (91%) 307 (98%) 164 (86%) 35 (64%) 
 
4 (67%) 




Family history of coronary 








     None 300 (54%) 180 (57%) 96 (51%) 24 (44%) 
 
3 (50%) 









MELD: Model for End-stage Liver Disease. * Unable to calculate p-value because of small cell values; † 3 
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Table 4. Utility of pre-liver transplant stress echocardiography testing in predicting coronary artery 






echocardiogram Positive 15 48 63 
 
Negative 26 378 404 
  
41 426 467 
     
     
 
Sensitivity 15/41*100 37% 












































































































































































Patient survival post-liver transplant (months)
Catheterization normal
Catheterization normal
Severe CAD requiring intervention



















































































MI within 1 Year
(p=0.81)
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